A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04241835 |
Recruitment Status :
Recruiting
First Posted : January 27, 2020
Last Update Posted : January 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatic Impairment Advanced Malignant Solid Tumor | Drug: Tazemetostat | Phase 1 |
The study will be conducted in 2 parts for subjects with advanced malignancies and either normal liver function, or advanced malignancies and moderate, or severe hepatic impairment. Subjects in Part 1 of the study will receive a single oral, 800 mg dose of tazemetostat on Day 1 and Day 15. In addition, the subjects will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 5 to Day 14. Blood samples for PK analysis will be obtained on Day 1 through Day 4 and again on Day 15 through Day 18. Part 1 ends on Day 18.
Subjects continuing treatment in Part 2 will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily in repeated 28-day cycles beginning on Day 19 until Investigator-assessed clinical progression per standard practice, or unacceptable toxicity, or until another discontinuation criterion is met. Subjects must have an end of study visit after 30 days of the last dose of tazemetostat for safety assessment. Supplementary study conduct information not mandated to be present in this protocol is provided in the accompanying procedure manuals (i.e., laboratory, pharmacy, ECG manuals). Such manuals will provide the site personnel with administrative and detailed technical information that does not impact subject safety.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies |
Actual Study Start Date : | January 28, 2020 |
Estimated Primary Completion Date : | May 2021 |
Estimated Study Completion Date : | May 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Open label Tazemetostat
Single and BID doses of oral tazemetostat 800 mg
|
Drug: Tazemetostat
200 mg and 400 mg tablets 200 mg: Round, red, biconvex, film-coated tablets 400 mg: Oval, red, biconvex, film-coated tablets Dose/Route/Schedule/Duration: Oral/twice daily/continuous Other Name: EPZ-6438 |
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-t: area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-∞: area under the plasma concentration-time curve from time 0 extrapolated to infinity [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, AUC0-72: area under the plasma concentration-time curve from time 0 to 72 hours post dose [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Cmax: observed maximum plasma concentration [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, Tmax: observed time at Cmax [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, λz: terminal phase elimination rate constant [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the pharmacokinetics (PK) of tazemetostat and its metabolite EPZ 6930, t1/2: terminal elimination half-life [ Time Frame: 0 to 72 hours post dose on Day 1 and Day 15 ]When administered as a single and multi-dose in subjects with advanced malignancies and moderate or severe hepatic impairment, compared with subjects with advanced malignancies and normal hepatic function
- To evaluate the number of participants with treatment-emergent adverse events as assessed by CTCAE v5.0 [ Time Frame: Through study completion, an average of 1 year ]Severity of adverse events experienced by all subjects with at least 1 dose or partial dose of tazemetostat will be evaluated by the Investigator based on the CTCAE, version 5.0
- To evaluate the number of abnormalities or changes in intensity of conditions noted during the physical exam [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any new clinically significant findings (e.g., not noted at screening) or changes in intensity of conditions that occurred after the initial tazemetostat administration
- To evaluate change in blood pressure [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes from baseline in systolic and diastolic blood pressure measured in units of millimeters of mercury (mmHg)
- To evaluate change in heart rate [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes from baseline in heart rate measured in units of beats per minute (BPM)
- To evaluate change in body temperature [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes from baseline in body temperature measured in degrees Fahrenheit or Celsius
- To evaluate changes in concomitant medications [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any changes in concomitant medications from baseline in all subjects with at least 1 dose or partial dose of tazemetostat
- To evaluate change in electrical activity of the heartbeat, RR interval [ Time Frame: Through study completion, an average of 1 year ]Investigators will report any clinically significant changes from baseline in the RR interval (sec) as noted by a 12 lead electrocardiogram (ECG)
- To evaluate change in electrical activity of the heartbeat, PR interval [ Time Frame: Through study completion, an average of 1 year ]Investigators will report any clinically significant changes from baseline in the PR interval (sec) as noted by a 12 lead electrocardiogram (ECG)
- To evaluate change in electrical activity of the heartbeat, QRS complex [ Time Frame: Through study completion, an average of 1 year ]Investigators will report any clinically significant changes from baseline in the QRS complex (sec) as noted by a 12 lead electrocardiogram (ECG)
- To evaluate change in electrical activity of the heartbeat, QT interval [ Time Frame: Through study completion, an average of 1 year ]Investigators will report any clinically significant changes from baseline in the QT interval (sec) as noted by a 12 lead electrocardiogram (ECG)
- To evaluate changes in clinical laboratory values, hematology [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes in hematological clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges
- To evaluate changes in clinical laboratory values, serum chemistry [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes in serum chemistry clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges
- To evaluate changes in clinical laboratory values, urinalysis [ Time Frame: Through study completion, an average of 1 year ]Investigators will note any clinically significant changes in urinalysis clinical laboratory values from baseline in all subjects with at least 1 dose or partial dose of tazemetostat using laboratory reference ranges

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- Male or female ≥ 18 years age at the time of consent.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 (Appendix 1).
- Has the ability to understand informed consent and provided signed written informed consent.
- Life expectancy of > 3 months.
- Histologically and/or cytologically confirmed advanced metastatic or unresectable solid tumors has progressed after treatment for which there are no standard therapies available OR histologically and/or cytologically confirmed hematological malignancies that have relapsed, or refractory disease following at least 2 standard lines of systemic therapy for which there are no standard therapies available.
- Must have evaluable or measurable disease.
- Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤ Grade 1 per NCI CTCAE, Version 5.0 or are clinically stable and not clinically significant, at time of consent.
- All subjects must have completed any prior chemotherapy, targeted therapy and major surgery, ≥ 28 days before study entry. For daily or weekly chemotherapy without the potential for delayed toxicity, a washout period of 14 days may be acceptable, and questions related to this can be discussed with the Medical Monitor.
- Has adequate hematologic (bone marrow [BM] and coagulation factors), and renal function.
- Able to swallow and retain orally-administered medication and without clinically significant gastrointestinal abnormalities that could alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- Subjects with abnormal hepatic function will be eligible and will be grouped according to established criteria. Subjects with active hemolysis will be excluded.
- Manual differential with no significant morphologic abnormalities on complete blood count (CBC) testing.
- Male subjects must refrain from donating sperm starting at least 7 days before the planned first dose of tazemetostat until 3 months following the last dose of tazemetostat.
-
Male subjects with a female partner of childbearing potential must:
- Be vasectomized, or
- Remain abstinent or use a condom starting at least 7 days before the planned first dose of IP until 3 months following the last dose of IP
-
Female partners of male subjects who are of childbearing potential must also adhere to one of the following:
- Placement of an intrauterine device or intrauterine system.
- Established use of oral, injected, or implanted hormonal methods of contraception plus an additional barrier method.
- Progesterone-only oral contraception, where inhibition of ovulation is not the primary mode of action.
-
Women of childbearing potential:
- Must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of < 1% per year starting at least 7 days before the planned first dose of IP until 6 months following the last dose of IP
- Due to the potential of enzyme induction with tazemetostat, female subjects who use hormonal contraceptives should use an additional barrier method of birth control while on study treatment and for 6 months after discontinuation of study treatment.
- Barrier methods must always be supplemented with the use of a spermicide.
- Females of childbearing potential must have a negative serum pregnancy test at screening.
- Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec.
-
Subjects with diagnosed human immunodeficiency virus (HIV) are eligible to participate in the study if they meet the following criteria:
- No history of AIDS-defining opportunistic infections, or have not had an opportunistic infection within the past 12 months prior to enrollment.
- No history of AIDS-defining cancers (eg Kaposi's sarcoma, aggressive B-cell lymphoma, and invasive cervical cancer).
- Subjects may take prophylactic antimicrobials, however subjects that are taking specific antimicrobial drugs where there may be DDI or overlapping toxicities should be excluded from study participation.
- Subjects should be on established anti-retroviral therapy for at least 4 weeks, and have an HIV viral load of < 400 copies/mL prior to enrollment.
Exclusion Criteria:
- Prior exposure to tazemetostat or other inhibitor(s) of EZH2.
- Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam. Subject's with primary glioblastoma multiforme are excluded. NOTE: Subjects with clinically stable brain metastases are eligible to enroll in the study.
- Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders. Subjects on anticoagulation with low molecular weight heparin are allowed.
- Known hypersensitivity to any of the components of tazemetostat.
-
Concurrent investigational agent or anticancer therapy. NOTE: Megestrol (Megace) if used as an appetite stimulant is allowed.
- Concurrent treatment with bisphosphonates is permitted; however, treatment must be initiated prior to the first dose of study therapy. Prophylactic use of bisphosphonates in subjects without bone disease is not permitted, except for the treatment of osteoporosis.
- The concurrent use of all herbal supplements is prohibited during the study as the composition, PK, and metabolism of many herbal supplements are unknown.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.
- Have a known active infection with hepatitis B virus (HBV, as measured by positive hepatitis B surface antigen, hepatitis C virus (HCV, as measured by positive hepatitis C antibody), OR human T-cell lymphotropic virus 1. EXCEPTIONS: Subjects with a history of hepatitis B or C who have normal ALT and are hepatitis B surface antigen negative and/or have undetectable HCV RNA.
- Subjects taking medications that are known potent CYP3A4 inducers/inhibitors (including St. John's Wort)
- Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the diet and all foods that contain those fruits from 24 hours prior to the first dose of study drug until the last dose of study drug.
- Any condition or medical problem in addition to the underlying malignancy and organ dysfunction that the Investigator feels would pose unacceptable risk.
- Has thrombocytopenia, neutropenia, or anemia of grade ≥3 (per CTCAE 5.0 criteria) or any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).
- Has abnormalities known to be associated with MDS (e.g. del 5q, chr 7 abn) and multiple primary neoplasms (MPN) (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing
- Has a prior history of T-LBL/T-ALL.
- Ingestion of alcohol and smoking is not permitted any time during the study.
- History of drug abuse (including alcohol) within the last 6 months prior to screening.
- Severe hepatic encephalopathy (Grade >2) or degree of central nervous system (CNS) impairment which the Investigator considers sufficiently serious to interfere with the informed consent, the conduct, the completion, or the results of this trial, or constitutes an unacceptable risk to the subject.
- History of liver transplantation.
- Advanced ascites or ascites that require drainage and albumin supplementation, as judged by the Investigator.
- Acute damage of the liver with Grade 4 AST/ALT values at screening or admission

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04241835
Contact: Shefali Agarwal, MD | 617-229-7575 | clinicaltrials@epizyme.com |
United States, Illinois | |
Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Devalingam Mahalingam, MD | |
United States, Nevada | |
Comprehensive Cancer Center of Nevada | Recruiting |
Las Vegas, Nevada, United States, 89014 | |
Contact: Fadi Braiteh, MD | |
United States, Ohio | |
Gabrail Cancer Center | Recruiting |
Canton, Ohio, United States, 44718 | |
Contact: Nashat Gabrail, MD | |
United States, Texas | |
Mary Crowley Cancer Research | Recruiting |
Dallas, Texas, United States, 75230 | |
Contact: James Strauss, MD | |
Oncology Consultants - Texas Medical Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Julio Peguero, MD | |
Belgium | |
Antwerp University Hospital | Recruiting |
Edegem, Antwerp, Belgium, 2650 | |
Contact: Hans Prenen, MD | |
Cliniques Universitaires Saint-Luc | Recruiting |
Brussels, Belgium, 1200 | |
Contact: Ivan V Borbath, MD | |
France | |
Institut Bergonie | Recruiting |
Bordeaux Cedex, France, 33076 | |
Contact: Antoine Italiano, MD | |
Centre Oscar Lambret | Recruiting |
Lille, France, 59020 | |
Contact: Cyril Abdeddaim, MD | |
Hopital de la Timone | Recruiting |
Marseille, France, 13005 | |
Contact: Sebastien Salas, MD | |
Poland | |
Biokinetica S.A Przychodnia Jozefow | Recruiting |
Józefów, Mazowieckie, Poland, 05410 | |
Contact: Rafal Stec, MD | |
MedPolonia | Recruiting |
Poznań, Wielkopolskie, Poland, 60693 | |
Contact: Rodryg Ramlau, MD | |
Slovakia | |
Summit Clinical Research, s.r.o | Recruiting |
Bratislava, Slovakia, 831 01 | |
Contact: Viera Skarbova, MD |
Responsible Party: | Epizyme, Inc. |
ClinicalTrials.gov Identifier: | NCT04241835 |
Other Study ID Numbers: |
EZH-1201 |
First Posted: | January 27, 2020 Key Record Dates |
Last Update Posted: | January 8, 2021 |
Last Verified: | January 2021 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Liver Diseases Digestive System Diseases |